Using the starting and stopping criteria, vedolizumab (Entyvio^®) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response or non-response to anti-TNF treatment; for Crohn’s disease following loss of response or non-response to anti-TNF treatment and ustekinumab.

The risks and benefits of the off-label use of vedolizumab (Entyvio^®) for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.